Bristol-Myers Squibb (NYSE:BMY) Receives Consensus Recommendation of "Hold" from Brokerages

Bristol-Myers Squibb (NYSE:BMY - Get Free Report) has been given an average rating of "Hold" by the twenty-two research firms that are covering the company, Marketbeat Ratings reports. Two analysts have rated the stock with a sell rating, thirteen have given a hold rating, five have assigned a buy rating and two have assigned a strong buy rating to the company. The average 1-year price target among brokers that have covered the stock in the last year is $58.00.

BMY has been the topic of several analyst reports. William Blair reaffirmed a "market perform" rating on shares of Bristol-Myers Squibb in a research note on Friday, April 25th. UBS Group decreased their target price on shares of Bristol-Myers Squibb from $60.00 to $54.00 and set a "neutral" rating on the stock in a research note on Friday, April 11th. Jefferies Financial Group decreased their target price on shares of Bristol-Myers Squibb from $70.00 to $68.00 and set a "buy" rating on the stock in a research note on Wednesday, April 23rd. Argus raised shares of Bristol-Myers Squibb to a "hold" rating in a research note on Friday, April 25th. Finally, Wells Fargo & Company lifted their target price on shares of Bristol-Myers Squibb from $60.00 to $62.00 and gave the stock an "equal weight" rating in a research note on Friday, February 7th.

Bristol-Myers Squibb Trading Up 1.2%

BMY stock opened at $48.42 on Friday. The company has a market capitalization of $98.54 billion, a PE ratio of -10.95, a price-to-earnings-growth ratio of 2.07 and a beta of 0.38. Bristol-Myers Squibb has a one year low of $39.35 and a one year high of $63.33. The company's 50 day moving average price is $49.34 and its two-hundred day moving average price is $55.06. The company has a debt-to-equity ratio of 2.90, a quick ratio of 1.15 and a current ratio of 1.25.

Bristol-Myers Squibb (NYSE:BMY - Get Free Report) last posted its quarterly earnings results on Thursday, April 24th. The biopharmaceutical company reported $1.80 EPS for the quarter, topping the consensus estimate of $1.50 by $0.30. The firm had revenue of $11.20 billion for the quarter, compared to the consensus estimate of $10.77 billion. Bristol-Myers Squibb had a negative net margin of 18.53% and a positive return on equity of 13.93%. The business's revenue was down 5.6% compared to the same quarter last year. During the same period last year, the firm posted ($4.40) earnings per share. As a group, analysts predict that Bristol-Myers Squibb will post 6.74 earnings per share for the current fiscal year.

Insider Activity

In other news, EVP Samit Hirawat purchased 4,250 shares of the company's stock in a transaction that occurred on Friday, April 25th. The shares were bought at an average price of $47.58 per share, for a total transaction of $202,215.00. Following the purchase, the executive vice president now directly owns 83,513 shares in the company, valued at approximately $3,973,548.54. This trade represents a 5.36% increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Company insiders own 0.09% of the company's stock.

Hedge Funds Weigh In On Bristol-Myers Squibb

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Pinney & Scofield Inc. purchased a new stake in shares of Bristol-Myers Squibb during the 4th quarter valued at about $25,000. Park Square Financial Group LLC purchased a new stake in shares of Bristol-Myers Squibb during the 4th quarter valued at about $26,000. Fairway Wealth LLC purchased a new stake in shares of Bristol-Myers Squibb during the 4th quarter valued at about $28,000. Transce3nd LLC purchased a new stake in shares of Bristol-Myers Squibb during the 4th quarter valued at about $28,000. Finally, Global Wealth Strategies & Associates increased its holdings in Bristol-Myers Squibb by 137.5% in the 1st quarter. Global Wealth Strategies & Associates now owns 475 shares of the biopharmaceutical company's stock worth $29,000 after acquiring an additional 275 shares in the last quarter. Institutional investors own 76.41% of the company's stock.

About Bristol-Myers Squibb

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.